ATE440866T1 - Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten - Google Patents

Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten

Info

Publication number
ATE440866T1
ATE440866T1 AT04806128T AT04806128T ATE440866T1 AT E440866 T1 ATE440866 T1 AT E440866T1 AT 04806128 T AT04806128 T AT 04806128T AT 04806128 T AT04806128 T AT 04806128T AT E440866 T1 ATE440866 T1 AT E440866T1
Authority
AT
Austria
Prior art keywords
immunolobulines
nogo
neutralizing
treatment
neurological diseases
Prior art date
Application number
AT04806128T
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Alexandre Eon-Duval
Robert Ian Grundy
Farhana Hussain
Ruth Mcadam
Christopher Plumpton
Rabinder Kumar Prinjha
Paul Alexander Wilson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0329684A external-priority patent/GB0329684D0/en
Priority claimed from GB0329711A external-priority patent/GB0329711D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE440866T1 publication Critical patent/ATE440866T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04806128T 2003-12-22 2004-12-20 Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten ATE440866T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0329684A GB0329684D0 (en) 2003-12-22 2003-12-22 Method
GB0329711A GB0329711D0 (en) 2003-12-22 2003-12-22 Antibodies
PCT/GB2004/005325 WO2005061544A2 (en) 2003-12-22 2004-12-20 Nogo-a neutralising immunoglobulins for treatment of neurological diseases

Publications (1)

Publication Number Publication Date
ATE440866T1 true ATE440866T1 (de) 2009-09-15

Family

ID=34712703

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04806128T ATE440866T1 (de) 2003-12-22 2004-12-20 Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten

Country Status (27)

Country Link
US (4) US7988964B2 (de)
EP (3) EP1711530B1 (de)
JP (2) JP2007537145A (de)
KR (1) KR101150548B1 (de)
AR (1) AR048912A1 (de)
AT (1) ATE440866T1 (de)
AU (1) AU2004303585B2 (de)
BR (1) BRPI0417959A (de)
CA (1) CA2549956C (de)
CY (1) CY1110530T1 (de)
DE (1) DE602004022871D1 (de)
DK (1) DK1711530T3 (de)
ES (1) ES2330444T3 (de)
HR (1) HRP20090527T1 (de)
IL (1) IL176206A (de)
IS (1) IS2739B (de)
MA (1) MA28289A1 (de)
MX (1) MXPA06007190A (de)
MY (1) MY144612A (de)
NO (1) NO20062767L (de)
NZ (1) NZ548013A (de)
PL (1) PL1711530T3 (de)
PT (1) PT1711530E (de)
RU (1) RU2362780C2 (de)
SI (1) SI1711530T1 (de)
TW (1) TWI329649B (de)
WO (2) WO2005061544A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355666B1 (de) 2000-12-22 2012-06-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Verwendung von "repulsive guidance molecule" (rgm) und von dessen modulatoren
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
DK1711530T3 (da) 2003-12-22 2009-12-14 Glaxo Group Ltd Nogo-A-neutraliserende immunoglobuliner til behandling af neurologiske sygdomme
WO2007003421A2 (en) * 2005-07-05 2007-01-11 Glaxo Group Limited Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US8663635B2 (en) 2006-03-21 2014-03-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
US20090291976A1 (en) * 2006-06-27 2009-11-26 Peter Andrew Ferchmin Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CA2672120A1 (en) * 2006-12-07 2008-06-12 Novartis Ag Antagonistic antibodies against ephb3
US20100311767A1 (en) * 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
WO2009026117A2 (en) * 2007-08-16 2009-02-26 Glaxo Group Limited Novel compounds
JP5698534B2 (ja) 2007-11-02 2015-04-08 ノバルティス アーゲー 改良されたｎｏｇｏ−ａ結合分子およびその医薬的使用
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CA2720025A1 (en) * 2008-04-04 2009-10-08 The Regents Of The University Of California Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
US20110268729A1 (en) * 2008-07-11 2011-11-03 Bams Abila Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
MX2012006560A (es) 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
US8828390B2 (en) 2010-07-09 2014-09-09 Universitat Zurich Uses of NOGO-A inhibitors and related methods
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
WO2012051498A2 (en) * 2010-10-15 2012-04-19 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
US8790649B2 (en) 2010-10-29 2014-07-29 Immunogen, Inc. EGFR-binding molecules and immunoconjugates thereof
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
KR20140105765A (ko) 2011-11-21 2014-09-02 이뮤노젠 아이엔씨 EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법
US10774132B2 (en) * 2012-01-09 2020-09-15 The Scripps Research Instittue Ultralong complementarity determining regions and uses thereof
PE20190907A1 (es) 2012-01-27 2019-06-26 AbbVie Deutschland GmbH and Co KG Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
KR20150036398A (ko) 2012-07-05 2015-04-07 글락소 그룹 리미티드 근육위축가쪽경화증의 치료에서의 항­ｎｏｇｏ­ａ 항체의 최적 투여 섭생
SG10202110908WA (en) 2015-05-04 2021-11-29 Cytomx Therapeutics Inc Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
US20180362660A1 (en) * 2016-05-09 2018-12-20 Schickwann Tsai Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes
EA202090247A1 (ru) * 2017-07-14 2020-05-12 Цитомкс Терапьютикс, Инк. Антитела против cd166 и их применения
AU2019232631A1 (en) 2018-03-05 2020-09-24 Janssen Pharmaceutica Nv Anti-PHF-tau antibodies and uses thereof
CN112672757A (zh) * 2018-09-25 2021-04-16 中央研究院 抗-唾液酸结合性免疫球蛋白样凝集素的抗体、包括该抗体的药学组合物及其用途
MX2022004737A (es) * 2019-10-24 2023-02-16 Novago Therapeutics Ag Anticuerpos anti-nogo-a novedosos.
CA3203749A1 (en) * 2020-12-02 2022-06-09 Agilent Technologies, Inc. Anti-human cd10 antibodies for use in immunohistochemistry (ihc) protocols to diagnose cancer
WO2024041450A1 (zh) * 2022-08-22 2024-02-29 舒泰神（北京）生物制药股份有限公司 特异性识别Nogo-A的抗体及其应用
CN116693672B (zh) * 2023-06-15 2025-08-08 郑州伊美诺生物技术有限公司 抗3型人副流感病毒单克隆抗体及其制备方法和应用
WO2025006549A2 (en) * 2023-06-28 2025-01-02 University Of Connecticut Antibodies against immune checkpoint molecules and methods of use
WO2026041734A1 (en) 2024-08-22 2026-02-26 Novago Therapeutics Ag Methods for treating neurological disorders using anti-nogo-a antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3935074A (en) * 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
ES2227769T3 (es) 1994-05-27 2005-04-01 Glaxosmithkline S.P.A. Derivados de quinolina como antagonistas del receptor nk3 de taquiquinina.
KR100728405B1 (ko) * 1998-11-06 2007-06-13 더 유니버시티 오브 취리히 Ｎｏｇｏ 유전자의 뉴클레오티드와 단백질 서열 및 이들에기초한 방법
FR2792199B3 (fr) * 1999-04-13 2001-05-18 Sanofi Sa Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur
US20030113891A1 (en) * 2000-02-11 2003-06-19 Lawrence Blatt Method and reagent for the inhibition of NOGO and NOGO receptor genes
GB0101313D0 (en) * 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
BR0309110A (pt) * 2002-04-17 2007-05-08 Upjohn Co composições e processo de tratamento da doença de alzheimer
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
MXPA05011100A (es) * 2003-04-16 2006-04-18 Univ Yale Antagonistas de receptor nogo para el tratamiento de condiciones que comprenden placas amiloideas.
GB0318727D0 (en) 2003-08-08 2003-09-10 Smithkline Beecham Corp Novel compounds
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
DK1711530T3 (da) * 2003-12-22 2009-12-14 Glaxo Group Ltd Nogo-A-neutraliserende immunoglobuliner til behandling af neurologiske sygdomme

Also Published As

Publication number Publication date
EP2213684A3 (de) 2011-05-18
IS2739B (is) 2011-06-15
JP2008504220A (ja) 2008-02-14
MY144612A (en) 2011-10-14
CA2549956A1 (en) 2005-07-07
US20110054149A1 (en) 2011-03-03
IL176206A (en) 2012-02-29
MA28289A1 (fr) 2006-11-01
KR101150548B1 (ko) 2012-07-06
TWI329649B (en) 2010-09-01
US7780964B2 (en) 2010-08-24
KR20060129290A (ko) 2006-12-15
WO2005061544A2 (en) 2005-07-07
AU2004303585A1 (en) 2005-07-07
TW200533680A (en) 2005-10-16
NZ548013A (en) 2009-04-30
NO20062767L (no) 2006-09-20
SI1711530T1 (sl) 2010-01-29
WO2005061545A2 (en) 2005-07-07
HRP20090527T1 (hr) 2009-11-30
WO2005061544A3 (en) 2005-08-18
EP1711530B1 (de) 2009-08-26
EP2213684A2 (de) 2010-08-04
JP4901480B2 (ja) 2012-03-21
CY1110530T1 (el) 2015-04-29
US7988964B2 (en) 2011-08-02
US20060029603A1 (en) 2006-02-09
RU2006123481A (ru) 2008-01-27
JP2007537145A (ja) 2007-12-20
DK1711530T3 (da) 2009-12-14
CA2549956C (en) 2016-04-12
EP1706426A2 (de) 2006-10-04
EP1711530A2 (de) 2006-10-18
IS8506A (is) 2006-06-12
AU2004303585B2 (en) 2010-12-23
US20070065430A1 (en) 2007-03-22
BRPI0417959A (pt) 2007-03-27
HK1100144A1 (en) 2007-09-07
PT1711530E (pt) 2009-10-22
PL1711530T3 (pl) 2010-01-29
WO2005061545A3 (en) 2005-08-18
RU2362780C2 (ru) 2009-07-27
ES2330444T3 (es) 2009-12-10
MXPA06007190A (es) 2006-08-23
AR048912A1 (es) 2006-06-14
DE602004022871D1 (de) 2009-10-08
US20140147435A1 (en) 2014-05-29
IL176206A0 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE374196T1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
DE60329123D1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
CY2015025I2 (el) Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
DE60322451D1 (de) 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
ATE313540T1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
GB0329874D0 (en) Compounds useful for the treatment of diseases
IL175535A (en) Compositions for treatment of neurodegenerative diseases
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
ATE423099T1 (de) Zur behandlung von schmerzen geeignete piperazine
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
ATE448228T1 (de) Pyrrolopyrimidinderivate zur behandlung proliferativer krankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1711530

Country of ref document: EP